دورية أكاديمية
أعرض في EDS

CD15 Expression Does Not Identify a Phenotypically or Genetically Distinct Glioblastoma Population.

التفاصيل البيبلوغرافية
العنوان: CD15 Expression Does Not Identify a Phenotypically or Genetically Distinct Glioblastoma Population.
المؤلفون: Kenney-Herbert E; John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, Cambridge University, Cambridge, United Kingdom; MRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, United Kingdom; The Institute of Cancer Research, London, United Kingdom cw209@cam.ac.uk emmakenneyherbert@yahoo.co.uk., Al-Mayhani T; John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, Cambridge University, Cambridge, United Kingdom; MRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, United Kingdom; The Institute of Cancer Research, London, United Kingdom., Piccirillo SG; John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, Cambridge University, Cambridge, United Kingdom; MRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, United Kingdom; The Institute of Cancer Research, London, United Kingdom., Fowler J; John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, Cambridge University, Cambridge, United Kingdom; MRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, United Kingdom; The Institute of Cancer Research, London, United Kingdom., Spiteri I; John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, Cambridge University, Cambridge, United Kingdom; MRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, United Kingdom; The Institute of Cancer Research, London, United Kingdom., Jones P; John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, Cambridge University, Cambridge, United Kingdom; MRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, United Kingdom; The Institute of Cancer Research, London, United Kingdom., Watts C; John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, Cambridge University, Cambridge, United Kingdom; MRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, United Kingdom; The Institute of Cancer Research, London, United Kingdom cw209@cam.ac.uk emmakenneyherbert@yahoo.co.uk.
المصدر: Stem cells translational medicine [Stem Cells Transl Med] 2015 Jul; Vol. 4 (7), pp. 822-31. Date of Electronic Publication: 2015 May 27.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 101578022 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2157-6564 (Print) Linking ISSN: 21576564 NLM ISO Abbreviation: Stem Cells Transl Med Subsets: PubMed not MEDLINE; MEDLINE
أسماء مطبوعة: Publication: 2022- : Oxford : Oxford University Press
Original Publication: Durham, NC : AlphaMed Press
مستخلص: Unlabelled: : Recent research has focused on the hypothesis that the growth and regeneration of glioblastoma (GB) is sustained by a subpopulation of self-renewing stem-like cells. This has led to the prediction that molecular markers for cancer stem cells in GB may provide a treatment target. One candidate marker is CD15: we wanted to determine if CD15 represented a credible stem cell marker in GB. We first demonstrated that CD15-positive (CD15+) cells were less proliferative than their CD15-negative (CD15-) counterparts in 10 patient GB tumors. Next we compared the proliferative activity of CD15+ and CD15- cells in vitro using tumor-initiating primary GB cell lines (TICs) and found no difference in proliferative behavior. Furthermore, TICs sorted for CD15+ and CD15- were not significantly different cytogenetically or in terms of gene expression profile. Sorted single CD15+ and CD15- cells were equally capable of reconstituting a heterogeneous population containing both CD15+ and CD15- cells over time, and both CD15+ and CD15- cells were able to generate tumors in vivo. No difference was found in the phenotypic or genomic behavior of CD15+ cells compared with CD15- cells from the same patient. Moreover, we found that in vitro, cells were able to interconvert between the CD15+ and CD15- states. Our data challenge the utility of CD15 as a cancer stem cell marker.
Significance: The data from this study contribute to the ongoing debate about the role of cancer stem cells in gliomagenesis. Results showed that CD15, a marker previously thought to be a cancer stem-like marker in glioblastoma, could not isolate a phenotypically or genetically distinct population. Moreover, isolated CD15-positive and -negative cells were able to generate mixed populations of glioblastoma cells in vitro.
(©AlphaMed Press.)
References: Neuro Oncol. 2010 Jan;12(1):49-57. (PMID: 20150367)
Cell. 2009 Sep 4;138(5):822-9. (PMID: 19737509)
Acta Neurochir (Wien). 2012 Jun;154(6):951-69; discussion 969. (PMID: 22527576)
Cancer. 1994 Oct 1;74(7):1921-6. (PMID: 7521787)
Cancer Res. 1994 Aug 1;54(15):3988-92. (PMID: 7518347)
Cancer Cell. 2012 Oct 16;22(4):425-37. (PMID: 23079654)
Am J Clin Pathol. 1992 Jun;97(6):876-84. (PMID: 1595610)
BMC Cancer. 2010;10:66. (PMID: 20181261)
Science. 2007 Jul 20;317(5836):337. (PMID: 17641192)
Trends Neurosci. 2002 Aug;25(8):417-22. (PMID: 12127759)
J Mol Med (Berl). 2009 Nov;87(11):1087-95. (PMID: 19784875)
Nature. 1994 Feb 17;367(6464):645-8. (PMID: 7509044)
J Neuropathol Exp Neurol. 1999 Nov;58(11):1113-24. (PMID: 10560654)
Nature. 2012 Jan 19;481(7381):306-13. (PMID: 22258609)
Pathology. 1983 Oct;15(4):373-8. (PMID: 6326028)
Cancer Res. 1964 Oct;24:1544-51. (PMID: 14234000)
Cell Stem Cell. 2014 Mar 6;14(3):275-91. (PMID: 24607403)
Evol Appl. 2013 Jan;6(1):102-8. (PMID: 23396760)
Nature. 2007 Jan 4;445(7123):106-10. (PMID: 17122772)
Nature. 2012 Aug 2;488(7409):49-56. (PMID: 22832581)
Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4009-14. (PMID: 23412337)
Development. 1994 Jan;120(1):135-41. (PMID: 8119122)
J Neurosci Methods. 2009 Jan 30;176(2):192-9. (PMID: 19215724)
Cell Stem Cell. 2009 Jun 5;4(6):568-80. (PMID: 19497285)
Neuro Oncol. 2012 May;14(5):596-612. (PMID: 22411914)
N Engl J Med. 2012 Mar 8;366(10):883-92. (PMID: 22397650)
Br J Cancer. 2011 Jun 7;104(12):1810-5. (PMID: 21610702)
Clin Neuropathol. 1994 Jan-Feb;13(1):1-11. (PMID: 7518371)
Neuro Oncol. 2011 Aug;13(8):830-45. (PMID: 21798846)
Nature. 2008 Dec 4;456(7222):593-8. (PMID: 19052619)
Acta Neuropathol. 2007 Aug;114(2):97-109. (PMID: 17618441)
Cell Stem Cell. 2009 Nov 6;5(5):466-7; author reply 468-9. (PMID: 19896437)
Nature. 2012 Feb 23;482(7386):529-33. (PMID: 22343890)
Neuron. 2002 Aug 29;35(5):865-75. (PMID: 12372282)
Cell Stem Cell. 2009 May 8;4(5):440-52. (PMID: 19427293)
Stat Appl Genet Mol Biol. 2004;3:Article3. (PMID: 16646809)
Stem Cell Reports. 2015 Jan 13;4(1):7-15. (PMID: 25533637)
Nature. 2011 Jan 20;469(7330):356-61. (PMID: 21160474)
Cell Stem Cell. 2009 Jun 5;4(6):466-7. (PMID: 19497271)
Cancer Res. 2010 Jun 1;70(11):4274-9. (PMID: 20460538)
Cancer Res. 2009 Jun 1;69(11):4682-90. (PMID: 19487286)
PLoS One. 2014;9(6):e98259. (PMID: 24906014)
Lab Invest. 2008 Aug;88(8):808-15. (PMID: 18560366)
Neurosci Lett. 2004 Oct 7;369(1):24-7. (PMID: 15380301)
Proc Natl Acad Sci U S A. 1976 Feb;73(2):549-53. (PMID: 1061157)
Dev Biol. 1981 Apr 30;83(2):391-8. (PMID: 6113181)
Int J Surg Pathol. 2010 Aug;18(4):255-9. (PMID: 19578047)
Nature. 2004 Nov 18;432(7015):396-401. (PMID: 15549107)
Transl Oncol. 2009 Dec;2(4):247-57. (PMID: 19956386)
Oncogene. 2009 Apr 16;28(15):1807-11. (PMID: 19287454)
Cancer Res. 2004 Oct 1;64(19):7011-21. (PMID: 15466194)
Bioinformatics. 2008 Jul 1;24(13):1547-8. (PMID: 18467348)
Cell. 2010 May 14;141(4):559-63. (PMID: 20478246)
Stem Cells. 2009 Aug;27(8):1722-33. (PMID: 19544433)
Dev Biol. 2006 Mar 15;291(2):300-13. (PMID: 16458284)
Histochem J. 1992 Nov;24(11):811-26. (PMID: 1362195)
Nature. 2001 Nov 1;414(6859):105-11. (PMID: 11689955)
Cancer Cell. 2010 Dec 14;18(6):655-68. (PMID: 21156287)
Neurol Clin. 1985 Nov;3(4):711-28. (PMID: 3001488)
Nature. 2007 Jan 4;445(7123):111-5. (PMID: 17122771)
Nat Med. 1997 Jul;3(7):730-7. (PMID: 9212098)
Nature. 2011 Jan 20;469(7330):362-7. (PMID: 21248843)
Cancer Res. 2007 May 1;67(9):4010-5. (PMID: 17483311)
Nature. 2006 Dec 7;444(7120):756-60. (PMID: 17051156)
Br J Cancer. 2012 Jul 24;107(3):462-8. (PMID: 22722315)
Nat Neurosci. 2005 Jul;8(7):865-72. (PMID: 15951811)
Cancer Cell. 2010 Nov 16;18(5):510-23. (PMID: 21075313)
Cancer Cell. 2010 Apr 13;17(4):362-75. (PMID: 20385361)
Proc Natl Acad Sci U S A. 1978 Nov;75(11):5565-9. (PMID: 281705)
Cell. 1990 Feb 23;60(4):585-95. (PMID: 1689217)
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8. (PMID: 12629218)
Cancer Lett. 2011 Jun 1;305(1):50-7. (PMID: 21402437)
Cancer Res. 2015 Jan 1;75(1):194-202. (PMID: 25406193)
Glia. 2011 Aug;59(8):1169-80. (PMID: 21446047)
Science. 1976 Oct 1;194(4260):23-8. (PMID: 959840)
Cell. 2012 Mar 30;149(1):36-47. (PMID: 22464322)
J Neuropathol Exp Neurol. 1997 Jul;56(7):798-805. (PMID: 9210876)
فهرسة مساهمة: Keywords: CD15; Cancer; Glioblastoma; Hierarchy; SSEA1; Stem cell
تواريخ الأحداث: Date Created: 20150529 Latest Revision: 20191120
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC4479614
DOI: 10.5966/sctm.2014-0047
PMID: 26019225
قاعدة البيانات: MEDLINE
الوصف
تدمد:2157-6564
DOI:10.5966/sctm.2014-0047